- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05426655
Effects of a Self-management Program for Temporomandibular Myalgia in Subjects With Fibromyalgia: a Single Arm Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design Analytical, prospective experimental study: uncontrolled clinical trial.
Population and study sample The study sample will be made up of subjects diagnosed with fibromyalgia who present with local myalgia, myofascial pain or referred myofascial pain in the temporomandibular region, according to the diagnostic criteria (DC/TMD). The subjects will be recruited after the mandatory acceptance and authorization by the corresponding bodies, during a recruitment period of approximately eight weeks, through different associations of fibromyalgia patients.
Intervention In a first visit, demographic data will be recorded and an examination will be performed to assess the presence of local myalgia, myofascial pain or referred myofascial pain in the temporomandibular region, according to the diagnostic criteria (DC/TMD). You will also be given, to read and sign, the informed consent for participation in the study, as well as the data protection document. After this visit, the defined eligibility criteria (inclusion and exclusion) will be applied.
In a second visit, a preliminary assessment will be carried out that will consist of measuring the maximum oral opening with and without pain, pressure pain threshold in the temporomandibular joint and masseter and temporal muscles, and the level of pain in the temporomandibular joint. In addition, the subject will have to fill out a questionnaire on different aspects such as jaw function, quality of life related to oral health, kinesiophobia, anxiety and depression, sleep, patient expectations, patient habits, catastrophizing, knowledge about pain, central sensitization , self-efficacy, and coping with pain.
One week later, the intervention program will begin. The program will consist of 3 sessions (visits 3, 4 and 5) in which everything related to pain and its management will be explained. In a first workshop, a first educational session on the neurophysiology of pain will be given by means of a Power point presentation. In a second workshop, a tool will be used to locate those factors that can improve/worse the pain, physical documentation will be delivered with instructions for performing a self-massage and exercises of the temporomandibular region as well as advice and recommendations to manage different situations that may appear on a daily basis and on Lifestyle. A meditation session will also be held. In the third and last workshop, the game "the painometer" will be played and a meditation session will be held.
On a sixth visit, 4 weeks after the end of the program, a new measurement and assessment will be taken. This measurement will be very similar to the one performed on the second visit, except for 1 variable: the patient's expectations will not be recorded, and the patient's satisfaction with the treatment received will be recorded. The objective will be to record the changes produced after the application of the treatment program.
On a seventh visit, at 6 months (medium-term follow-up), all the measurements and assessments made on the sixth visit will be repeated, with the aim of recording their status after six months.
At an eighth visit, at 12 months (long-term follow-up), all the measurements and assessments made at the seventh visit will be repeated, with the aim of recording their status after twelve months.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: J. Édgar Ferrández-Gómez
- Phone Number: +34663063594
- Email: edgarferrandez@gmail.com
Study Locations
-
-
-
Murcia, Spain, 30004
- Recruiting
- FIBROFAMUR (Asociación fibromialgia de Murcia)
-
Contact:
- Phone Number: 688921300
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults over 18 years old.
- Subjects diagnosed with fibromyalgia.
- Orofacial pain of at least 3 months of evolution (considered chronic, according to IASP).
- Presence of myalgia, local myalgia, myofascial pain or referred myofascial pain in the temporomandibular region (according to DC/TMD).
Exclusion Criteria:
- Internal temporal-romandibular joint disorder with anterior disc displacement, joint pathology (arthritis), facial paralysis (active), mandibular fracture (active), infectious-inflammatory picture of odontogenic origin (active).
- Pregnancy.
- Neuropsychiatric pathologies (schizophrenia, bipolarity, cognitive alteration).
- Subjects receiving any other physiotherapy treatment in the mandibular region.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Self management
Intervention group: education in pain neuroscience + self-massage + exercises + advice and recommendations.
|
The program will consist of 3 sessions in which everything related to pain and its management will be explained.
In a first workshop, a first educational session on the neurophysiology of pain will be given by means of a Power Point presentation.
In a second workshop, a tool will be used to locate those factors that can improve/worse the pain, physical documentation will be delivered with instructions for performing a self-massage and exercises of the temporomandibular region as well as advice and recommendations to manage different situations that may appear on a daily basis and on Lifestyle.
A meditation session will also be held.
In the third and last workshop, the game "the painometer" will be played and a meditation session will be held.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from the Baseline in the Oral Health-Related Quality of Life (OHRQoL)
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Spanish version of Oral Health Impact Profile 5 items (OHIP-5 items).Responses are presented on a 5-point ordinal scale (0, never; 1, hardly ever; 2, occasionally; 3, fairly often; and 4, very often).
Summing all responses resulted in a score ranging from a minimum of 0 to a maximum of 20.
A larger score indicated more negative impacts of oral health problems.
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from the Baseline in the Fear of temporomandibular movement (kinesiophobia)
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Assessed with the Spanish version of Tampa Scale for Temporomandibular Joint Disorder, an 11-item scale.
The score for each item ranges from 0 (totally disagree) to 4 (totally agree), the higher the score, the greater the degree of kinesiophobia.
The optimal cut-off point for considering kinesiophobia is 23 points.
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Change from the Baseline in pain maladaptation
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Assessed with the Spanish version of Pain Catastrophizing Scale.
It is a self-administered scale of 13 items.
It comprises 3 dimensions: rumination; magnification and despair.
Each item is valued from 0 to 4, with the maximum score being 52 points.
The higher the score, the higher degree of catastrophizing.
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Change from the Baseline in symptoms related to central sensitization
Time Frame: Baseline, 4 weeks after the end of the intervention at month 6, at month 12.
|
Assessed with the Spanish version of Central Sensitization Inventory.
It is divided in 2 parts.
Part A contains a list of 25 items about how often the person experiences each symptom ("never, rarely, sometimes, often, or always").
Individual items are scored from "0" (never) to "4" (always), resulting in a total score range for all 25 items from "0" to "100."
Part B is about if the person has been previously diagnosed with seven common central sensitization diagnoses (tension headaches/migraines, fibromyalgia, irritable bowel syndrome, restless leg syndrome, temporomandibular joint disorder, chronic fatigue syndrome, and multiple chemical sensitivities) and three central sensitization-related diagnoses (depression, anxiety/panic attacks, and neck injury).
This part is for information only and is not scored.
A score of 40 or higher has been recommended as a reasonable cutoff.
|
Baseline, 4 weeks after the end of the intervention at month 6, at month 12.
|
Change from the Baseline in self-efficacy expectations
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Assessed with the Spanish version of Chronic Self-efficacy Scale.
It is a scale of 19 questions divided into 3 parts.
The first part (8 questions) refers to whether the subject believes they are capable of carrying out different activities.
The second part (6 questions) refers to whether the subject believes they are capable of carrying out a series of activities without help.
The third part (5 questions) refers to the ability that the subject believes he has, at this time, to carry out a series of activities.
The subject responds using an 11-point Likert-type scale (0=I do not think I am capable at all, 10=I think I am totally capable).
The maximum score is 190 points.
The higher the score, the higher the degree of self-efficacy.
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Change from the Baseline in pain coping strategies
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Assessed with Reduced Chronic Pain Coping Strategies Questionnaire.
It is a scale of 24 items.
It is answered on a 5-point Likert scale (never = 1, always = 5).
The first-order scales are religion (use of religious beliefs), catharsis (seeking social emotional support), distraction (avoidance by paying attention to pain), self-affirmation (not fainting, encouraging oneself), mental self-control (mental control of pain) and search for information (advice, queries about what to do).
The second-order scales are called active strategies (distraction, mental self-control, self-affirmation, and information seeking) and passive strategies (religion and catharsis).
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Change from the Baseline in the Range of Motion of the Temporomandibular Joint
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Measured with a ruler (expressed in centimeters).
Normal mobility is considered from 4.5 centimeters.
It is measured maximum mouth opening with and without pain.
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Change from the Baseline in the Pain Pressure Threshold
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Measured with an algometer, expressed in Kg/Cm2.
It is performed on the mandibular condyle and both masseter and temporal muscles, bilaterally.
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Change from the Pain intensity
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Evaluated with the numerical rating scale for pain.
It's An 11-point numeric scale with 0 representing one pain extreme ("no pain") and 10 representing the other pain extreme ("pain as bad as you can imagine" and "worst pain imaginable").
The subject is asked to indicate the numeric value on the segmented scale that best describes their pain intensity.
Higher scores indicate greater pain intensity.
A reduction of approximately two points or a reduction of approximately 30% represented a clinically important difference.
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Change from the Baseline in the functional status of the masticatory system
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Assessed with the Spanish version of Jaw Functional Limitation Scale-8 (JFLS8).
A scale that evaluates 8 items on a scale from 0 (no limitation) to 10 (severe limitation).
The higher the score, the greater the limitation.
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Change from the Baseline in sleep difficulties
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Assessed with Athens Insomnia Scale.
It is an 8-item scale.
Participants are asked to score each item from 0 (no problem at all) to 3 (very serious problem).
The total score ranges from 0 to 24.
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Change from the Baseline in emotional state
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Assessed with the Spanish version of Hospital Anxiety and Depression Scale.
14-item questionnaire.
Two subscales of 7 items each, on a 0-3 Likert scale.
Odd items assess anxiety, even items assess depression, with a score range in each subscale of 0-21.
Higher score, greater anxiety and depression.
For both subscales, the authors suggest that scores greater than eleven would indicate "case" and greater than eight would be considered "probable case".
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Change from the Baseline in oral behaviors
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Assessed with the Spanish version of Oral Behaviors Checklist.
It's a self-reported questionnaire (diagnostic criteria for temporomandibular disorder, axis II assessment) used to identify and quantify the frequency of different oral habits.
It is conformed by 21 questions, with each having 5 possible answers: none of the time=0; a little of the time=1; some of the time=2; most of the time=3; and all of the time=4.
For the first 2 questions, which are about oral habits that occur at night, the possible answers are: none of the time=0; <1 night per month=1; 1 to 3 nights per month=2; 1 to 3 nights per week=3; and 4 to 7 nights per week=4.
A score of 3 or 4 indicated that the patient had that particular oral habit.
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Change from the knowledge about neurophysiology of pain and conceptualization of pain
Time Frame: Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Assessed with the Spanish version of Neurophysiology of Pain Questionnaire.
It contains 12 items relating to the neurophysiology of pain.
Each item has three response options: true, false, undecided.
It is scored out of 12 with 1 point awarded for each correct response.
A score of 0 is attributed to incorrect responses and those marked as undecided.
The higher the score, the greater the knowledge about the neurophysiology of pain.
|
Baseline, 4 weeks after the end of the intervention, at month 6, at month 12.
|
Treatment expectations
Time Frame: Pre-intervention
|
Assessed with a questionnaire proposed by Puentedura et al (Development of a Clinical Prediction Rule to Identify Patients With Neck Pain Likely to Benefit From Thrust Joint Manipulation to the Cervical Spine).
In this proposal, the subject is asked if he thinks that the treatment can help him.
There are 5 possible responses: completely disagree, slightly disagree, neutral, somewhat agree, completely agree.
The treatments they ask about are: education in the physiology of pain, jaw mobility exercises, jaw strength exercises, sleep hygiene, relaxation techniques, rest, avoiding bad oral habits, medication, surgery.
|
Pre-intervention
|
Degree of satisfaction with the intervention
Time Frame: 4 weeks after the end of the intervention
|
Assessed with the Spanish version of Consumer Reports Effectiveness Scale (CRES-4).
It consists of 4 items: a satisfaction question, a question to rate the degree of resolution of the main problem, a question about the emotional state before starting treatment and, finally, a question about the emotional state at the time of answering.
To obtain the global score of the CRES-4, the results of the previous components are added together as represented by the following formula: CRES-4 = (20 x satisfaction) + (20 x problem solution) + [12.5 x (4 + current emotional state - pre-treatment emotional state)] Therefore, to interpret the CRES-4 globally, a score on a scale ranging from 0 to 300 points is considered.
The higher the total score, the more effective the treatment according to the patient.
|
4 weeks after the end of the intervention
|
Adverse effects
Time Frame: 4 weeks after the end of the intervention
|
Questionnaire in which you will be asked if you have had adverse effects.
If so, the subject will be asked to specify what it consists of.
|
4 weeks after the end of the intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: J. Édgar Ferrández-Gómez, Universidad de Murcia
Publications and helpful links
General Publications
- Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, List T, Svensson P, Gonzalez Y, Lobbezoo F, Michelotti A, Brooks SL, Ceusters W, Drangsholt M, Ettlin D, Gaul C, Goldberg LJ, Haythornthwaite JA, Hollender L, Jensen R, John MT, De Laat A, de Leeuw R, Maixner W, van der Meulen M, Murray GM, Nixdorf DR, Palla S, Petersson A, Pionchon P, Smith B, Visscher CM, Zakrzewska J, Dworkin SF; International RDC/TMD Consortium Network, International association for Dental Research; Orofacial Pain Special Interest Group, International Association for the Study of Pain. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Groupdagger. J Oral Facial Pain Headache. 2014 Winter;28(1):6-27. doi: 10.11607/jop.1151.
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
- Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Kosek E, Lavand'homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ. A classification of chronic pain for ICD-11. Pain. 2015 Jun;156(6):1003-1007. doi: 10.1097/j.pain.0000000000000160. No abstract available.
- Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52. doi: 10.1002/acr.20543. No abstract available.
- Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001 Nov;94(2):149-158. doi: 10.1016/S0304-3959(01)00349-9.
- Watson JA, Ryan CG, Cooper L, Ellington D, Whittle R, Lavender M, Dixon J, Atkinson G, Cooper K, Martin DJ. Pain Neuroscience Education for Adults With Chronic Musculoskeletal Pain: A Mixed-Methods Systematic Review and Meta-Analysis. J Pain. 2019 Oct;20(10):1140.e1-1140.e22. doi: 10.1016/j.jpain.2019.02.011. Epub 2019 Mar 1.
- Ohrbach R, Larsson P, List T. The jaw functional limitation scale: development, reliability, and validity of 8-item and 20-item versions. J Orofac Pain. 2008 Summer;22(3):219-30.
- Boonstra AM, Schiphorst Preuper HR, Reneman MF, Posthumus JB, Stewart RE. Reliability and validity of the visual analogue scale for disability in patients with chronic musculoskeletal pain. Int J Rehabil Res. 2008 Jun;31(2):165-9. doi: 10.1097/MRR.0b013e3282fc0f93.
- Louw A, Zimney K, Puentedura EJ, Diener I. The efficacy of pain neuroscience education on musculoskeletal pain: A systematic review of the literature. Physiother Theory Pract. 2016 Jul;32(5):332-55. doi: 10.1080/09593985.2016.1194646. Epub 2016 Jun 28.
- Nijs J, Paul van Wilgen C, Van Oosterwijck J, van Ittersum M, Meeus M. How to explain central sensitization to patients with 'unexplained' chronic musculoskeletal pain: practice guidelines. Man Ther. 2011 Oct;16(5):413-8. doi: 10.1016/j.math.2011.04.005. Epub 2011 May 31.
- Scerbo T, Colasurdo J, Dunn S, Unger J, Nijs J, Cook C. Measurement Properties of the Central Sensitization Inventory: A Systematic Review. Pain Pract. 2018 Apr;18(4):544-554. doi: 10.1111/papr.12636. Epub 2017 Nov 20.
- Salvetti G, Manfredini D, Bazzichi L, Bosco M. Clinical features of the stomatognathic involvement in fibromyalgia syndrome: a comparison with temporomandibular disorders patients. Cranio. 2007 Apr;25(2):127-33. doi: 10.1179/crn.2007.019.
- Cuesta-Vargas AI, Roldan-Jimenez C, Neblett R, Gatchel RJ. Cross-cultural adaptation and validity of the Spanish central sensitization inventory. Springerplus. 2016 Oct 21;5(1):1837. doi: 10.1186/s40064-016-3515-4. eCollection 2016.
- Garcia Campayo J, Rodero B, Alda M, Sobradiel N, Montero J, Moreno S. [Validation of the Spanish version of the Pain Catastrophizing Scale in fibromyalgia]. Med Clin (Barc). 2008 Oct 18;131(13):487-92. doi: 10.1157/13127277. Spanish.
- Visscher CM, Ohrbach R, van Wijk AJ, Wilkosz M, Naeije M. The Tampa Scale for Kinesiophobia for Temporomandibular Disorders (TSK-TMD). Pain. 2010 Sep;150(3):492-500. doi: 10.1016/j.pain.2010.06.002. Epub 2010 Jul 3.
- Catley MJ, O'Connell NE, Moseley GL. How good is the neurophysiology of pain questionnaire? A Rasch analysis of psychometric properties. J Pain. 2013 Aug;14(8):818-27. doi: 10.1016/j.jpain.2013.02.008. Epub 2013 May 4.
- Kapos FP, Exposto FG, Oyarzo JF, Durham J. Temporomandibular disorders: a review of current concepts in aetiology, diagnosis and management. Oral Surg. 2020 Nov;13(4):321-334. doi: 10.1111/ors.12473. Epub 2020 Jan 25.
- Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O'Neill E. Factor structure, reliability, and validity of the Pain Catastrophizing Scale. J Behav Med. 1997 Dec;20(6):589-605. doi: 10.1023/a:1025570508954.
- Stepanski EJ, Wyatt JK. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev. 2003 Jun;7(3):215-25. doi: 10.1053/smrv.2001.0246.
- Michelotti A, de Wijer A, Steenks M, Farella M. Home-exercise regimes for the management of non-specific temporomandibular disorders. J Oral Rehabil. 2005 Nov;32(11):779-85. doi: 10.1111/j.1365-2842.2005.01513.x.
- Best N, Best S, Loudovici-Krug D, Smolenski UC. Measurement of mandible movements using a vernier caliper--an evaluation of the intrasession-, intersession- and interobserver reliability. Cranio. 2013 Jul;31(3):176-80. doi: 10.1179/crn.2013.028.
- Di Venere D, Corsalini M, Stefanachi G, Tafuri S, De Tommaso M, Cervinara F, Re A, Pettini F. Quality of life in fibromyalgia patients with craniomandibular disorders. Open Dent J. 2015 Jan 30;9:9-14. doi: 10.2174/1874210601509010009. eCollection 2015.
- Santiago V, Raphael KG. Perceived helpfulness of treatments for myofascial TMD as a function of comorbid widespread pain. Clin Oral Investig. 2019 Jul;23(7):2929-2939. doi: 10.1007/s00784-018-02797-6. Epub 2019 Jan 8.
- Kim, Hyunjoong, and Seungwon Lee. Effects of Pain Neuroscience Education on Kinesiophobia in Patients with Chronic Pain: A Systematic Review and Meta-Analysis. Physical Therapy Rehabilitation Science. 2020 Dec; 9(4):309-317. doi:10.14474/ptrs.2020.9.4.309.
- Leake HB, Moseley GL, Stanton TR, O'Hagan ET, Heathcote LC. What do patients value learning about pain? A mixed-methods survey on the relevance of target concepts after pain science education. Pain. 2021 Oct 1;162(10):2558-2568. doi: 10.1097/j.pain.0000000000002244.
- Shala R, Roussel N, Lorimer Moseley G, Osinski T, Puentedura EJ. Can we just talk our patients out of pain? Should pain neuroscience education be our only tool? J Man Manip Ther. 2021 Feb;29(1):1-3. doi: 10.1080/10669817.2021.1873259. Epub 2021 Jan 11. No abstract available.
- Siddall B, Ram A, Jones MD, Booth J, Perriman D, Summers SJ. Short-term impact of combining pain neuroscience education with exercise for chronic musculoskeletal pain: a systematic review and meta-analysis. Pain. 2022 Jan 1;163(1):e20-e30. doi: 10.1097/j.pain.0000000000002308.
- Shaffer SM, Brismee JM, Courtney CA, Sizer PS. The status of temporomandibular and cervical spine education in credentialed orthopedic manual physical therapy fellowship programs: a comparison of didactic and clinical education exposure. J Man Manip Ther. 2015 Feb;23(1):51-6. doi: 10.1179/2042618614Y.0000000087.
- Romm MJ, Ahn S, Fiebert I, Cahalin LP. A Meta-Analysis of Therapeutic Pain Neuroscience Education, Using Dosage and Treatment Format as Moderator Variables. Pain Pract. 2021 Mar;21(3):366-380. doi: 10.1111/papr.12962. Epub 2020 Nov 22.
- Figueiro C, Knorst JK, Fensterseifer CK, Folchini S, Milanesi JM, Bernardon Silva T, Marquezan M. Changes in oral health-related quality of life after self-care treatment in patients with myofascial pain. Cranio. 2021 Apr 30:1-7. doi: 10.1080/08869634.2021.1922229. Online ahead of print.
- de Freitas RF, Ferreira MA, Barbosa GA, Calderon PS. Counselling and self-management therapies for temporomandibular disorders: a systematic review. J Oral Rehabil. 2013 Nov;40(11):864-74. doi: 10.1111/joor.12098. Epub 2013 Sep 18.
- Michelotti A, Iodice G, Vollaro S, Steenks MH, Farella M. Evaluation of the short-term effectiveness of education versus an occlusal splint for the treatment of myofascial pain of the jaw muscles. J Am Dent Assoc. 2012 Jan;143(1):47-53. doi: 10.14219/jada.archive.2012.0018.
- Aggarwal VR, Wu J, Fox F, Howdon D, Guthrie E, Mighell A. Implementation of biopsychosocial supported self-management for chronic primary oro-facial pain including temporomandibular disorders: A theory, person and evidence-based approach. J Oral Rehabil. 2021 Oct;48(10):1118-1128. doi: 10.1111/joor.13229. Epub 2021 Jul 27.
- Eliassen M, Hjortsjo C, Olsen-Bergem H, Bjornland T. Self-exercise programmes and occlusal splints in the treatment of TMD-related myalgia-Evidence-based medicine? J Oral Rehabil. 2019 Nov;46(11):1088-1094. doi: 10.1111/joor.12856. Epub 2019 Jul 21.
- Michelotti A, Steenks MH, Farella M, Parisini F, Cimino R, Martina R. The additional value of a home physical therapy regimen versus patient education only for the treatment of myofascial pain of the jaw muscles: short-term results of a randomized clinical trial. J Orofac Pain. 2004 Spring;18(2):114-25. Erratum In: J Orofac Pain. 2006 Spring;20(2):106.
- Shimada A, Ishigaki S, Matsuka Y, Komiyama O, Torisu T, Oono Y, Sato H, Naganawa T, Mine A, Yamazaki Y, Okura K, Sakuma Y, Sasaki K. Effects of exercise therapy on painful temporomandibular disorders. J Oral Rehabil. 2019 May;46(5):475-481. doi: 10.1111/joor.12770. Epub 2019 Feb 19.
- Haggman-Henrikson B, Wiesinger B, Wanman A. The effect of supervised exercise on localized TMD pain and TMD pain associated with generalized pain. Acta Odontol Scand. 2018 Jan;76(1):6-12. doi: 10.1080/00016357.2017.1373304. Epub 2017 Sep 4.
- Gomes MB, Guimaraes JP, Guimaraes FC, Neves AC. Palpation and pressure pain threshold: reliability and validity in patients with temporomandibular disorders. Cranio. 2008 Jul;26(3):202-10. doi: 10.1179/crn.2008.027.
- Simancas-Pallares M, John MT, Enstad C, Lenton P. The Spanish Language 5-Item Oral Health Impact Profile. Int Dent J. 2020 Apr;70(2):127-135. doi: 10.1111/idj.12534. Epub 2019 Nov 20.
- John MT, Omara M, Su N, List T, Sekulic S, Haggman-Henrikson B, Visscher CM, Bekes K, Reissmann DR, Baba K, Schierz O, Theis-Mahon N, Fueki K, Stamm T, Bondemark L, Oghli I, van Wijk A, Larsson P. RECOMMENDATIONS FOR USE AND SCORING OF ORAL HEALTH IMPACT PROFILE VERSIONS. J Evid Based Dent Pract. 2022 Mar;22(1):101619. doi: 10.1016/j.jebdp.2021.101619. Epub 2021 Aug 10.
- La Touche R, Pardo-Montero J, Cuenca-Martinez F, Visscher CM, Paris-Alemany A, Lopez-de-Uralde-Villanueva I. Cross-Cultural Adaptation and Psychometric Properties of the Spanish Version of the Tampa Scale for Kinesiophobia for Temporomandibular Disorders. J Clin Med. 2020 Sep 1;9(9):2831. doi: 10.3390/jcm9092831.
- Cabrera V, Martín-Aragón M, Terol M, Núñez R, Pastor M. Escala de Ansiedad y Depresión Hospitalaria (HAD) en fibromialgia: Análisis de sensibilidad y especificidad. La Terapia psicológica. 2015; 33(3): 181-193. https://dx.doi.org/10.4067/S0718-48082015000300003
- Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry. 2003 Jul-Aug;25(4):277-83. doi: 10.1016/s0163-8343(03)00043-4.
- Enomoto K, Adachi T, Yamada K, Inoue D, Nakanishi M, Nishigami T, Shibata M. Reliability and validity of the Athens Insomnia Scale in chronic pain patients. J Pain Res. 2018 Apr 16;11:793-801. doi: 10.2147/JPR.S154852. eCollection 2018.
- Gomez-Benito J, Ruiz C, Guilera G. A Spanish version of the Athens Insomnia Scale. Qual Life Res. 2011 Aug;20(6):931-7. doi: 10.1007/s11136-010-9827-x. Epub 2011 Jan 6.
- Puentedura EJ, Cleland JA, Landers MR, Mintken PE, Louw A, Fernandez-de-Las-Penas C. Development of a clinical prediction rule to identify patients with neck pain likely to benefit from thrust joint manipulation to the cervical spine. J Orthop Sports Phys Ther. 2012 Jul;42(7):577-92. doi: 10.2519/jospt.2012.4243. Epub 2012 May 14.
- Feixas G, Pucurull O, Roca C, Paz C, García-Grau E, Bados A. Escala de satisfacción con el tratamiento recibido (CRES-4): La versión en español. Revista de Psicoterapia. 2012; 23(89): 51-58. DOI: 10.33898/rdp.v23i89.639
- Xu L, Cai B, Fan S, Lu S, Dai K. Association of Oral Behaviors with Anxiety, Depression, and Jaw Function in Patients with Temporomandibular Disorders in China: A Cross-Sectional Study. Med Sci Monit. 2021 May 17;27:e929985. doi: 10.12659/MSM.929985.
- Haggman-Henrikson B, M Visscher C, Wanman A, Ljotsson B, C Peck C, Lovgren A. Even mild catastrophic thinking is related to pain intensity in individuals with painful temporomandibular disorders. J Oral Rehabil. 2021 Nov;48(11):1193-1200. doi: 10.1111/joor.13251. Epub 2021 Sep 15.
- Torres-Lacomba M, Navarro-Brazalez B, Bailon-Cerezo J, Vergara-Perez F, de la Rosa-Diaz I, Prieto-Gomez V. Assessment Tools of Patient Competences: The Spanish Version of the R-NPQ and Three Practical Cases in Women with Breast Cancer and Persistent Pain. Int J Environ Res Public Health. 2021 Apr 22;18(9):4463. doi: 10.3390/ijerph18094463.
- Neblett R, Hartzell MM, Cohen H, Mayer TG, Williams M, Choi Y, Gatchel RJ. Ability of the central sensitization inventory to identify central sensitivity syndromes in an outpatient chronic pain sample. Clin J Pain. 2015 Apr;31(4):323-32. doi: 10.1097/AJP.0000000000000113.
- Neblett R, Hartzell MM, Mayer TG, Cohen H, Gatchel RJ. Establishing Clinically Relevant Severity Levels for the Central Sensitization Inventory. Pain Pract. 2017 Feb;17(2):166-175. doi: 10.1111/papr.12440. Epub 2016 Mar 15.
- Martín-Aragón M, Pastor M.A, Rodríguez-Marín J, Marcha M.J, Lledó A, López-Roig. Percepción de autoeficacia en dolor crónico. Adaptación y validación de la Chronic Pain Self-efficacy Scale. Revista de Psicología de la Salud. 1999;11(1):51-76. DOI: https://doi.org/10.21134/pssa.v11i1.799
- Pastor J, Monsalve V. Validation of the reduced chronic pain coping questionnaire (CAD-R). Revista de la Sociedad Española del Dolor. 1 de octubre de 2004;11(7):407-14.
- Lindfors E, Magnusson T, Ernberg M. Effect of Therapeutic Jaw Exercises in the Treatment of Masticatory Myofascial Pain: A Randomized Controlled Study. J Oral Facial Pain Headache. 2020 Fall;34(4):364-373. doi: 10.11607/ofph.2670.
- Brain K, Burrows TL, Rollo ME, Chai LK, Clarke ED, Hayes C, Hodson FJ, Collins CE. A systematic review and meta-analysis of nutrition interventions for chronic noncancer pain. J Hum Nutr Diet. 2019 Apr;32(2):198-225. doi: 10.1111/jhn.12601. Epub 2018 Oct 7.
- Nijs J, Roose E, Lahousse A, Mostaqim K, Reynebeau I, De Couck M, Beckwee D, Huysmans E, Bults R, van Wilgen P, Leysen L. Pain and Opioid Use in Cancer Survivors: A Practical Guide to Account for Perceived Injustice. Pain Physician. 2021 Aug;24(5):309-317.
- do-Nascimento R, Maia J, de-Medeiros S, Silva HJ, Lins C, Souza MC. Pain education to women with fibromyalgia using the DolorÔmetro game. Brazilian Journal Of Pain. 2020; 3(2): 131-135. http://dx.doi.org/10.5935/2595-0118.20200026
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Musculoskeletal Pain
- Stomatognathic Diseases
- Jaw Diseases
- Craniomandibular Disorders
- Mandibular Diseases
- Myalgia
- Fibromyalgia
- Myofascial Pain Syndromes
- Temporomandibular Joint Disorders
- Temporomandibular Joint Dysfunction Syndrome
Other Study ID Numbers
- EFG012022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
-
Yousra Hisham Abdel FattahCompletedFibromyalgia, PrimaryEgypt
-
Forest LaboratoriesCypress Bioscience, Inc.TerminatedPrimary FibromyalgiaUnited States
-
Universidade Federal do Rio Grande do NorteCompleted
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
University of ManitobaCompleted
Clinical Trials on Self management
-
Radboud University Medical CenterCompleted
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedMultiple Sclerosis | Low Back Pain | Chronic Pain | Muscular Dystrophies | Spinal Cord Injury | Other and Unspecified Amputation Stump ComplicationsUnited States
-
University of RochesterVisiting Nurse Service of New YorkCompleted
-
University of North Carolina, Chapel HillCenters for Disease Control and PreventionCompletedChronic DiseaseUnited States
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedHeavy Drinking | Harmful; Use, AlcoholUnited States
-
OsakidetzaFondo de Investigacion Sanitaria; Kronikgune-- Association Centre of International... and other collaboratorsCompleted
-
VA Office of Research and DevelopmentCompletedObstructive Sleep ApneaUnited States
-
University of OklahomaNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingDiabetes Mellitus | Cholesterol, Elevated
-
Hamilton Health Sciences CorporationCompleted
-
University of South FloridaNational Cancer Institute (NCI)CompletedCancer | Unspecified Adult Solid Tumor, Protocol Specific | Psychological StressUnited States, Puerto Rico